블록버스터 항암제 브랜드 시장 규모, 점유율 및 동향 분석 보고서 : 브랜드별, 치료법별, 유통 채널별, 지역별 및 부문별 전망(2026-2033년)

The global blockbuster oncology brands market size was valued at USD 47.2 billion in 2025 and is projected to grow from USD 51.0 billion in 2026 to USD 87.4 billion by 2033, at a CAGR of 8.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 38.0% in 2025. The rising prevalence of various cancer types across different age groups, coupled with ongoing advancements in oncology research, is driving market growth.

In addition, the expanding availability of innovative treatment approaches, including immunotherapies, targeted therapies, and cellular therapies, is providing patients with a broader range of therapeutic options, further supporting market expansion.

A blockbuster drug is a highly sought-after drug that generates annual sales of USD 1 billion or more for a pharmaceutical company. Regulatory bodies worldwide have accelerated approval rates for new drug therapies as first-line treatments. In addition, companies have invested heavily in research and development efforts for new drug formulations. These factors have collectively contributed to the high growth trajectory of the global market for blockbuster oncology brands.

In January 2026, according to the American Cancer Society (ACS) in its Cancer Statistics, an estimated 2.1 million new cancer cases and 0.6 million cancer deaths are expected to occur in the United States. The most common types of cancer, according to IARC, were lung and prostate cancer for men and breast cancer for women. Such a large and expanding patient population encourages pharmaceutical companies to accelerate the development of innovative oncology therapies. These new drug therapies come at a high cost to patients; however, favorable reimbursement policies are supporting the commercial success of blockbuster oncology brands and contributing to overall market growth.

Regulatory bodies worldwide, such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare Products Regulatory Agency (MHRA), and others, have fast-tracked their approval rates for the application of innovative drug therapies in cancer treatment, such as targeted immunotherapy, CAR-T cell therapy, monoclonal antibodies, and many others. Tailored treatment approaches employed by oncologists, based on genetic and molecular profiling of tumors, further enhance treatment efficacy and drive market demand.

Global Blockbuster Oncology Brands Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global blockbuster oncology brands market report based on brands, treatment, distribution channel, and region:

• Brands Outlook (Revenue, USD Billion, 2021 - 2033)

Opdivo

Keytruda

Perjeta

Ibrance

Tecentriq

Gazyva

Tagrisso

Darzalex

Zejula

Revlimid

Imbruvica

Others

• Treatment Outlook (Revenue, USD Billion, 2021 - 2033)

Lung cancer

Breast cancer

Multiple myeloma

Lymphoma

Others

• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

Hospital Pharmacy

Retail Pharmacy

Other

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

• U.S.
• Canada
• Mexico

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia Pacific

• Japan
• India
• China
• Australia
• South Korea
• Thailand

Latin America

• Brazil
• Argentina

Middle East and Africa

• South Africa
• Saudi Arabia
• UAE
• Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Blockbuster Oncology Brands Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Billion)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Blockbuster Oncology Brands Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political Landscape
    • 3.4.2.2. Economic and Social Landscape
    • 3.4.2.3. Technological Landscape
    • 3.4.2.4. Environmental Landscape
    • 3.4.2.5. Legal Landscape

Chapter 4. Blockbuster Oncology Brands Market: Brands Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Blockbuster Oncology Brands Market: Brands Movement Analysis, 2025 & 2033 (USD Billion)
• 4.3. Opdivo
  • 4.3.1. Opdivo Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.4. Keytruda
  • 4.4.1. Keytruda Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.5. Perjeta
  • 4.5.1. Perjeta Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.6. Ibrance
  • 4.6.1. Ibrance Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.7. Tecentriq
  • 4.7.1. Tecentriq Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.8. Gazyva
  • 4.8.1. Gazyva Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.9. Tagrisso
  • 4.9.1. Tagrisso Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.10. Darzalex
  • 4.10.1. Darzalex Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.11. Zejula
  • 4.11.1. Zejula Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.12. Revlimid
  • 4.12.1. Revlimid Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.13. Imbruvica
  • 4.13.1. Imbruvica Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.14. Others
  • 4.14.1. Other Brands Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Blockbuster Oncology Brands Market: Treatment Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Blockbuster Oncology Brands Market: Treatment Movement Analysis, 2025 & 2033 (USD Billion)
• 5.3. Lung Cancer
  • 5.3.1. Lung Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.4. Breast Cancer
  • 5.4.1. Breast Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.5. Multiple Myeloma
  • 5.5.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.6. Lymphoma
  • 5.6.1. Lymphoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.7. Others
  • 5.7.1. Other Treatments Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Blockbuster Oncology Brands Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Blockbuster Oncology Brands Market: Distribution Channel Movement Analysis, 2025 & 2033 (USD Billion)
• 6.3. Hospital Pharmacy
  • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.4. Retail Pharmacy
  • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.5. Other
  • 6.5.1. Other Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Blockbuster Oncology Brands Market: Regional Estimates & Trend Analysis

• 7.1. Blockbuster Oncology Brands Market Share, By Region, 2025 & 2033 (USD Billion)
• 7.2. North America
  • 7.2.1. North America Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.3. Europe
  • 7.3.1. Europe Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.3.2. U.K.
    • 7.3.2.1. U.K. Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.3.4. France
    • 7.3.4.1. France Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.2. China
    • 7.4.2.1. China Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.3. Japan
    • 7.4.3.1. Japan Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.4. India
    • 7.4.4.1. India Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.6. Australia
    • 7.4.6.1. Australia Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.5. Latin America
  • 7.5.1. Latin America Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Saudi Arabia Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.3. South Africa
    • 7.6.3.1. South Africa Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.4. UAE
    • 7.6.4.1. UAE Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Blockbuster Oncology Brands Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Bristol-Myers Squibb Company
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. Merck & Co., Inc.
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Pfizer Inc.
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. F. Hoffmann-La Roche Ltd
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. AstraZeneca
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. GSK plc
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Novartis AG
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Johnson & Johnson Services, Inc.
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. AbbVie Inc.
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Amgen Inc.
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives